Recommendations for Federal Partners and Health Departments Navigating Naloxone Supply

July 19th, 2021

In Spring 2021, pharmaceutical manufacturers and distributors notified syringe services programs (SSPs) and partners that there would be significant interruptions in the supply of generic injectable/intramuscular (IM) naloxone. Currently, production and distribution delays are expected to last until fall 2021. This will specifically affect SSPs because IM naloxone is the most affordable formulation, and therefore highly utilized by programs aiming to distribute naloxone at volumes that most affect fatal overdose rates.

On July 19th, NASTAD hosted a webinar with Buyers Club to discuss the recently released resource, Recommendations for Federal Partners and Health Departments Navigating Naloxone Supply. This resource was developed by NASTAD’s Drug User Health Team, in consultation with harm reduction consultants that have been instrumental in creating access to low-cost naloxone for syringe services programs (SSPs) and people who use drugs (PWUD) across the country. Topics during the webinar included reviewing the new guidance, hearing updates from national, state, and local naloxone access programs, and discussing strategies for management, communication, and working with SSPs.

Webinar Recording